DPG Media operates as a media company. The Company provides wide range of news such as entertainment, sports, politics, market, and other related stories, as well as offers advertising services. DPG Media serves customers in Belgium.
Inbiose NV researches, develops, and produces specialty carbohydrates and related products. It develops fermentation based technology platform suitable for the industrial manufacturing of specialty carbohydrate, called glycans, and produces human milk oligosaccharides (HMO, fucosylated, and sialylated oligosaccharides), infant nutrition, probiotics nutraceuticals, and cosmetic products that helps immune defenses, brain development, gastro-intestinal disorder, anti-microbial and viruses defence mechanisms. The company produces specialty carbohydrates and sugars, such as L-fucose, L-ribose, and sialic acid or human milk oligosaccharides such as fucosyllactose, and sialyllactose; human milk bioactives also called Human Milk Oligosaccharides (HMO), for infant food formula (milk bioactives), fortified and functional food/beverages, health ingredients for human and animal, and over the counter food supplements; and prebiotics and probiotics. It also offers biological system feasibility studies (strain construction and proof of concept); development of upstream fermentation protocols and scale-up for specialty carbohydrate targets through access to pilot plant facilities; fermentation optimization (strain platform screening); downstream process design and development; and research contracts and manufacturing contracts. The company serves human and animal nutraceuticals, biomedical, and agro industries. It has partnership with private or public institutions, KOLs in scientific and life science communities, industrial/medical food manufacturers, pharmaceutical companies, and animal or plant health companies in form of licensing-out, licensing-in, co-development, contract manufacturing, and third party services. The company was founded in 2013 and is based in Ghent, Belgium.
Bone Therapeutics is a leading international biopharmaceutical company focused on innovative cell therapy products for the treatment of bone diseases. Utilizing the Company's unique knowledge of the bone/joint physiology and long-standing expertise in cell therapy and cell transplantation, Bone Therapeutics has created a fully integrated business with an advanced product pipeline comprising novel bone cell products, tailored in-house production methods, and minimally invasive treatment techniques.
Enevo Oy develops the Enevo, an analytic software that collects and analyzes data points to measure waste and recycling generation. It provides a waste management analytics solution that uses ultrasonic sonar technology to detect fill levels for commercial clients, haulers, and cities. The company offers insights to clients handling waste contracts to streamline their waste management operations. It serves customers through resellers in the Netherlands, Belgium, Norway, and other countries in Europe. Enevo Oy was incorporated in 2010 and is headquartered in Espoo, Finland with additional offices in the United States, the United Kingdom, Germany, and Japan.